BioIntelliSense announced FDA approval for its new BioButton multi-patient wearable and BioDashboard system, expanding its portfolio of continuous patient monitoring solutions. This rechargeable, reusable device automates vital sign collection in hospital settings, providing scalable monitoring across multiple medical units, including emergency departments. The BioButton also extends hospital-level care to patients at home, reducing the burden on healthcare providers.

The BioDashboard system, designed to monitor multiple patients at once, offers customizable alerts to assist proactive clinical decision-making. It integrates with third-party electronic medical records (EMR) and cloud-based platforms, improving workflow efficiency by automating vital sign documentation. According to the company, this system enables one clinician to manage hundreds of patients simultaneously, ensuring personalized care with automated notifications and trending updates.

This FDA clearance follows BioIntelliSense’s recent partnership with iRhythm and prior collaborations with Medtronic and Philips. Dr. James Mault, CEO of BioIntelliSense, highlighted that this technology sets a new standard in continuous patient care by offering unprecedented economies of scale, making high-quality care accessible to all admitted patients.

Click here to read the original news story.